HMGA2 and ovarian carcinoma: These results collectively suggest that INAVA inhibits HMGA2pS105 level to promote HMGA2‐mediated STAT3 transcriptional activation, consequently inducing NOF activation, which contributes to poorer prognosis in patients with ovarian cancer.